Current lymphoma therapies are a far cry from the mustard gas used more than 50 years ago. More treatment options, including ones that may be more effective and less toxic, are being studied in ongoing clinical trials.
“Clinical trials really are the future of lymphoma treatment,” says Ann LaCasce, MD, a medical oncologist in the Adult Lymphoma Program at Dana-Farber/Brigham and Women’s Cancer Center.
More than 70 years ago, two pharmacologists began looking at mustard gas as a possible treatment for lymphoma. The chemical, used during World War I, lowered blood counts and destroyed lymph nodes in soldiers who were exposed to the gas.
Two decades after the war, a thoracic surgeon named Gustav Lindskog used nitrogen mustard to successfully treat a patient with non-Hodgkin’s lymphoma.
New Year’s Eve 2010. In a military hospital in Hawaii with much of the staff away for the holidays, Army pilot Ben Groen learned he’d been diagnosed with T cell lymphoblastic non-Hodgkin lymphoma, a rare, aggressive cancer of the white blood cells and lymph nodes. His doctor told him that his treatment – which would need to begin almost immediately and require months of hospitalization – would exceed the capacity of the base’s blood bank.